T-03
Monitoring panel: what the trials measured
No approved label directs enclomiphene monitoring. This panel assembles, lab by lab, what the clinical program actually measured, what moved, and which class schedules from approved alternatives are worth borrowing, with a symptoms row the regulators would insist on.
Review-gated tool: this tool is excluded from search and AI citation. It is not hormone, fertility, dosing, monitoring, or treatment guidance and has no named clinician review.
No approved label directs enclomiphene monitoring. This panel assembles, lab by lab, what the clinical program actually measured, what moved, and which class schedules from approved alternatives are worth borrowing, with a symptoms row the regulators would insist on.
Published records (9 of 9)
| Measure | What the trials showed | Practical note |
|---|---|---|
| Total testosterone (morning) | Rose into the normal range at every studied dose; 604 +/- 160 ng/dL on 25 mg at week 6 | Morning draws; the program used two confirmatory low values to enroll |
| LH and FSH | Rose on enclomiphene (above normal range in phase II); suppressed on testosterone gel | Distinguishes stimulation from replacement; also the enrollment gate (LH below 9.4 IU/L) |
| Estradiol | Rose on clomiphene in men (17 to 34 pg/mL long-term; significantly elevated in the 400-man series); fell modestly on enclomiphene in the switch series (-5.92 pg/mL) | The lab where the two SERMs measurably differ |
| Semen analysis | Concentration maintained in normal range on enclomiphene through 16 weeks; marked reduction on gel | Only relevant if fertility matters; no pregnancy outcomes exist |
| Hematocrit and hemoglobin | Higher on testosterone gel than enclomiphene in pooled program data | Borrow the testosterone-label schedule: baseline, 3-6 months, then annually; elevated hematocrit is a guideline reason not to start testosterone |
| PSA | Clinically insignificant increases on enclomiphene in pooled data; rose when clomiphene raised endogenous testosterone in an early series | Age-appropriate prostate monitoring applies to raised endogenous testosterone too |
| Lipids, TSH, ACTH, cortisol, bone markers | No significant changes over 6 weeks; IGF-1 fell (unexplained) | IGF-1 decline is a flagged open question from the phase II paper |
| Symptoms (energy, libido, mood, erectile function) | Never a measured endpoint in the program; the EMA refusal turned on exactly this absence | If symptoms drove the prescription and do not improve on a monitored trial, the rising number is not the win it looks like |
| Vision | Class warning from the clomiphene label: blurring, spots or flashes require stopping and an eye exam; blurred vision reported by men on long-term clomiphene | Treat the class flag as applying until shown otherwise |
Every row restates a published record; sources resolve on the sourced monograph. Species is part of the data: this table never scales an animal dose into a human figure.
Worked example
Worked example
Tools: educational calculators and references only.